By SPC News Staff
The FDA approved a new indication for certolizumab pegol (Cimzia, UCB) to treat moderate to severe plaque psoriasis in adults.
Certolizumab pegol (CZP) is indicated for patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. CZP is an Fc-free, pegylated anti–tumor necrosis factor (TNF) product, which has a high affinity for human TNF-alpha, selectively neutralizing its pathophysiologic effects.
“The phase 3